Our study has revealed that Cytoplasmic YAP1 could be utilized as prognostic factors in CRC patients and may be indicators of whether a certain patient population could benefit from postoperative chemotherapy, however, the molecular mechanisms behind it remain unknown and need to be further investigated. This evidence concerns the gene YAP1 and colorectal carcinoma.